CN109843927A - 抗b7-h3抗体、其抗原结合片段及其医药用途 - Google Patents

抗b7-h3抗体、其抗原结合片段及其医药用途 Download PDF

Info

Publication number
CN109843927A
CN109843927A CN201880003854.1A CN201880003854A CN109843927A CN 109843927 A CN109843927 A CN 109843927A CN 201880003854 A CN201880003854 A CN 201880003854A CN 109843927 A CN109843927 A CN 109843927A
Authority
CN
China
Prior art keywords
seq
antibody
sequence
antigen
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN201880003854.1A
Other languages
English (en)
Other versions
CN109843927B (zh
Inventor
闫树德
葛虎
张连山
曹国庆
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Changzhou Hengbang Pharmaceutical Co ltd
Hansen Shanghai Health Technology Co ltd
Original Assignee
Jiangsu Hengrui Medicine Co Ltd
Shanghai Hengrui Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jiangsu Hengrui Medicine Co Ltd, Shanghai Hengrui Pharmaceutical Co Ltd filed Critical Jiangsu Hengrui Medicine Co Ltd
Publication of CN109843927A publication Critical patent/CN109843927A/zh
Application granted granted Critical
Publication of CN109843927B publication Critical patent/CN109843927B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/14—Fungi; Culture media therefor
    • C12N1/16—Yeasts; Culture media therefor
    • C12N1/165—Yeast isolates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C12N1/205—Bacterial isolates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C12R2001/185—Escherichia
    • C12R2001/19—Escherichia coli
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/645—Fungi ; Processes using fungi
    • C12R2001/84—Pichia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/91—Cell lines ; Processes using cell lines

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Botany (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

提供了抗B7‑H3的抗体、其抗原结合片段及包含所述抗体或抗原结合片段的药物组合物。还提供了所述抗体或抗原结合片段在制备用于治疗B7‑H3介导的疾病或病症的药物中的用途。所述抗体可以是鼠源抗体、嵌合抗体、人源化抗体或人抗体。所述药物组合物可以用于治疗癌症。

Description

PCT国内申请，说明书已公开。

Claims (20)

  1. PCT国内申请，权利要求书已公开。
CN201880003854.1A 2017-03-06 2018-03-05 抗b7-h3抗体、其抗原结合片段及其医药用途 Active CN109843927B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2017101290236 2017-03-06
CN201710129023 2017-03-06
PCT/CN2018/078011 WO2018161872A1 (zh) 2017-03-06 2018-03-05 抗b7-h3抗体、其抗原结合片段及其医药用途

Publications (2)

Publication Number Publication Date
CN109843927A true CN109843927A (zh) 2019-06-04
CN109843927B CN109843927B (zh) 2022-06-21

Family

ID=63447283

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201880003854.1A Active CN109843927B (zh) 2017-03-06 2018-03-05 抗b7-h3抗体、其抗原结合片段及其医药用途

Country Status (3)

Country Link
CN (1) CN109843927B (zh)
TW (1) TWI673287B (zh)
WO (1) WO2018161872A1 (zh)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021213478A1 (zh) * 2020-04-22 2021-10-28 复星凯特生物科技有限公司 抗人b7-h3的单克隆抗体及其应用
WO2023001154A1 (zh) * 2021-07-20 2023-01-26 广州爱思迈生物医药科技有限公司 一种b7-h3抗体及其应用
CN116178553A (zh) * 2022-02-25 2023-05-30 南京蓬勃生物科技有限公司 针对人b7-h3的抗体及其变体

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020018964A1 (en) 2018-07-20 2020-01-23 Fred Hutchinson Cancer Research Center Compositions and methods for controlled expression of antigen-specific receptors
CN109851673B (zh) * 2019-01-22 2023-07-25 苏州旭光科星抗体生物科技有限公司 一种抗人b7-h3单克隆抗体的制备方法及其免疫组化检测方法及其应用及其试剂盒
CN111454357B (zh) * 2019-08-14 2022-03-15 康诺亚生物医药科技（成都）有限公司 一种含有抗体的肿瘤治疗剂的开发和应用
US20220332829A1 (en) * 2019-09-16 2022-10-20 Nanjing Sanhome Pharmaceutical Co., Ltd. Anti-b7-h3 antibody and application thereof
CN110642948B (zh) * 2019-10-09 2021-06-29 达石药业(广东)有限公司 B7-h3纳米抗体、其制备方法及用途
US20230014398A1 (en) * 2019-11-18 2023-01-19 Board Of Regents, The University Of Texas System Anti-b7-h3 monoclonal antibody and methods of use thereof
CN113754766A (zh) * 2020-06-02 2021-12-07 明慧医药（上海）有限公司 抗b7-h3抗体及其制备和应用
JP2023551721A (ja) * 2020-12-02 2023-12-12 ▲邁▼威（上海）生物科技股▲フン▼有限公司 抗ヒトｂ７－ｈ３抗体及びその利用
CN114380910B (zh) * 2022-01-07 2023-04-28 苏州旭光科星抗体生物科技有限公司 靶向人b7-h3分子的人源化单克隆抗体及其应用
TW202400248A (zh) * 2022-06-07 2024-01-01 中國大陸商映恩生物製藥（蘇州）有限公司 抗b7h3抗體-藥物結合物及其用途

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG183847A1 (en) * 2010-03-04 2012-10-30 Macrogenics Inc Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof
TW201249869A (en) * 2011-04-25 2012-12-16 Daiichi Sankyo Co Ltd Anti B7-H3 antibody
CN104961829A (zh) * 2009-11-24 2015-10-07 米迪缪尼有限公司 针对b7-h1的靶向结合剂
WO2016033225A2 (en) * 2014-08-27 2016-03-03 Memorial Sloan Kettering Cancer Center Antibodies, compositions, and uses
CN105682740A (zh) * 2013-07-09 2016-06-15 安尼艾克松股份有限公司 抗-补体因子c1q抗体及其应用
CN109963591A (zh) * 2017-08-04 2019-07-02 江苏恒瑞医药股份有限公司 B7h3抗体-药物偶联物及其医药用途
CN112543771A (zh) * 2018-09-30 2021-03-23 江苏恒瑞医药股份有限公司 抗b7h3抗体-依喜替康类似物偶联物及其医药用途

Patent Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104961829A (zh) * 2009-11-24 2015-10-07 米迪缪尼有限公司 针对b7-h1的靶向结合剂
SG183847A1 (en) * 2010-03-04 2012-10-30 Macrogenics Inc Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof
CN106279416A (zh) * 2010-03-04 2017-01-04 宏观基因有限公司 与b7‑h3反应性的抗体、其免疫学活性片段及其用途
TW201707724A (zh) * 2010-03-04 2017-03-01 宏觀基因股份有限公司 反應b7-h3之抗體、其免疫活性片段及使用
TW201249869A (en) * 2011-04-25 2012-12-16 Daiichi Sankyo Co Ltd Anti B7-H3 antibody
CN103687945A (zh) * 2011-04-25 2014-03-26 第一三共株式会社 抗-b7-h3抗体
CN105682740A (zh) * 2013-07-09 2016-06-15 安尼艾克松股份有限公司 抗-补体因子c1q抗体及其应用
WO2016033225A2 (en) * 2014-08-27 2016-03-03 Memorial Sloan Kettering Cancer Center Antibodies, compositions, and uses
CN109963591A (zh) * 2017-08-04 2019-07-02 江苏恒瑞医药股份有限公司 B7h3抗体-药物偶联物及其医药用途
CN112543771A (zh) * 2018-09-30 2021-03-23 江苏恒瑞医药股份有限公司 抗b7h3抗体-依喜替康类似物偶联物及其医药用途

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
DERYK LOO等: "Development of an Fc-Enhanced Anti–B7-H3 Monoclonal Antibody with Potent Antitumor Activity", 《CLIN CANCER RES.》 *
邱天宇等: "人B7-H3两种异构体基因转染细胞株的构建及鼠抗人B7-H3单克隆抗体的研制", 《中国优秀硕士学位论文全文数据库》 *

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021213478A1 (zh) * 2020-04-22 2021-10-28 复星凯特生物科技有限公司 抗人b7-h3的单克隆抗体及其应用
WO2023001154A1 (zh) * 2021-07-20 2023-01-26 广州爱思迈生物医药科技有限公司 一种b7-h3抗体及其应用
CN116178553A (zh) * 2022-02-25 2023-05-30 南京蓬勃生物科技有限公司 针对人b7-h3的抗体及其变体
CN116589586A (zh) * 2022-02-25 2023-08-15 南京蓬勃生物科技有限公司 针对人b7-h3的抗体及其变体
CN116178553B (zh) * 2022-02-25 2023-11-17 南京蓬勃生物科技有限公司 针对人b7-h3的抗体及其变体
CN116589586B (zh) * 2022-02-25 2024-02-02 南京蓬勃生物科技有限公司 针对人b7-h3的抗体及其变体

Also Published As

Publication number Publication date
TW201833141A (zh) 2018-09-16
TWI673287B (zh) 2019-10-01
WO2018161872A1 (zh) 2018-09-13
CN109843927B (zh) 2022-06-21

Similar Documents

Publication Publication Date Title
CN109843927A (zh) 抗b7-h3抗体、其抗原结合片段及其医药用途
JP6983371B2 (ja) 抗ｐｄ−ｌ１抗体、その抗原結合フラグメントおよびその医療用途
CN110366560B (zh) 抗b7-h4抗体、其抗原结合片段及其医药用途
CN110267989B (zh) 抗cd40抗体、其抗原结合片段及其医药用途
WO2019141268A1 (zh) 抗4-1bb抗体、其抗原结合片段及其医药用途
CN112243443B (zh) 抗trop-2抗体、其抗原结合片段及其医药用途
WO2019184935A1 (zh) 抗cd27抗体、其抗原结合片段及其医药用途
CN112969714A (zh) 抗cd40抗体、其抗原结合片段及其医药用途
CN110461874B (zh) 抗gitr抗体、其抗原结合片段及其医药用途
CN115298216A (zh) 抗体或其抗原结合片段、其制备方法及医药用途
CN113227148A (zh) 抗gpc3抗体、其抗原结合片段及其医药用途
RU2792748C2 (ru) Антитело к b7-h4, его антигенсвязывающий фрагмент и его фармацевтическое применение
RU2779128C2 (ru) Антитело к cd40, его антигенсвязывающий фрагмент и его медицинское применение
WO2022078424A1 (zh) 抗trop-2抗体、其抗原结合片段或其突变体、及其医药用途

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
TR01 Transfer of patent right
TR01 Transfer of patent right

Effective date of registration: 20231211

Address after: Room 101, No. 287 Xiangke Road and No. 1158 Haike Road, China (Shanghai) Pilot Free Trade Zone, Pudong New Area, Shanghai, October 2012

Patentee after: Hansen (Shanghai) Health Technology Co.,Ltd.

Patentee after: Changzhou Hengbang Pharmaceutical Co.,Ltd.

Address before: 222047 No. 7 Kunlun Shan Road, Lianyungang economic and Technological Development Zone, Jiangsu

Patentee before: JIANGSU HENGRUI MEDICINE Co.,Ltd.

Patentee before: SHANGHAI HENGRUI PHARMACEUTICAL Co.,Ltd.